1. Montelukast exhibited positive effects on remission maintenance in ulcerative colitis patients.
2. The study recruited 222 patients with ulcerative colitis for a double-blind randomized controlled trial.
3. Patients receiving montelukast showed longer relapse-free periods compared to the placebo group.
4. The study found statistically significant differences in inflammatory biomarkers between the montelukast and placebo groups.
5. Exclusion criteria included patients with cardiovascular diseases, kidney or lung failure, and recent use of certain medications.
6. Montelukast is suggested as a valuable addition to managing ulcerative colitis, especially during corticosteroid tapering.
7. The study acknowledges limitations, such as the lack of endoscopic remission assessment and the short follow-up duration post-montelukast discontinuation.

Source: BMJ Open Gastroenterology